Sign inCreate account

Report workspace

Add to folder
NCT01203124COMPLETEDanonymous

A Single-blind, Randomized, Placebo Controlled, Parallel-group, Adaptive-design Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 Administered Intranasally for up to 7 Days, on the Biomarker

Sponsor

Source record

AstraZeneca

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Immunological and inflammatory response modulation via biomarkers such as CXCL 10 (IP-10) and mRNA expression of IFNα regulated genes.

Indication / condition

AI-normalized

Healthy Volunteers

Intervention

Source record

AZD8848, Placebo

Source & freshness

Source record

NCT ID

NCT01203124

Original source

ClinicalTrials.gov

Source last updated

Aug 14, 2015

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01203124

Title

A Single-blind, Randomized, Placebo Controlled, Parallel-group, Adaptive-design Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 Administered Intranasally for up to 7 Days, on the Biomarker

Sponsor

AstraZeneca

Status

COMPLETED

Phase

Phase 1

Condition raw

Healthy Volunteers

Condition normalized

Healthy Volunteers

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Immunological and inflammatory response modulation via biomarkers such as CXCL 10 (IP-10) and mRNA expression of IFNα regulated genes.

Target normalized

Immunological and inflammatory response modulation via biomarkers such as CXCL 10 (IP-10) and mRNA expression of IFNα regulated genes.

Interventions

AZD8848, Placebo

Public preview

Source record

AZD8848, developed by AstraZeneca, is positioned to address unmet needs in immunological and inflammatory conditions. The study's adaptive design and focus on dosing frequency and response could provide critical insights into optimizing treatment regimens. Given the increasing demand for intranasal therapies, particularly in the context of respiratory diseases, AZD8848 may capture a significant share of this market. Competitive analysis indicates that while several intranasal therapies exist, AZD8848's unique mechanism and dosing flexibility could differentiate it from current offerings. Diligence efforts should focus on the regulatory landscape and potential partnerships for further development and commercialization.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Single-blind, Randomized, Placebo Controlled, Parallel-group, Adaptive-design Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 Administered Intranasally for up to 7 Days, on the Biomarker

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT01203124

Status

COMPLETED

Phase

Phase 1

Sponsor

AstraZeneca

Executive brief

Investment-Ready Snapshot

AZD8848, developed by AstraZeneca, is positioned to address unmet needs in immunological and inflammatory conditions. The study's adaptive design and focus on dosing frequency and response could provide critical insights into optimizing treatment regimens. Given the increasing demand for intranasal therapies, particularly in the context of respiratory diseases, AZD8848 may capture a significant share of this market. Competitive analysis indicates that while several intranasal therapies exist, AZD8848's unique mechanism and dosing flexibility could differentiate it from current offerings. Diligence efforts should focus on the regulatory landscape and potential partnerships for further development and commercialization.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 14, 2015
Internal syncJun 18, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01203124

Indication

Healthy Volunteers

Modality

small molecule

Target

Immunological and inflammatory response modulation via biomarkers such as CXCL 10 (IP-10) and mRNA expression of IFNα regulated genes.

Intervention

AZD8848, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.